HB 1584

86(R) - 2019
House Insurance
Senate Business & Commerce
House Insurance
Senate Business & Commerce

Companion Bill

SB 1184

Vote Recommendation

  • Neutral
  • Neutral
  • Neutral
  • Negative
  • Neutral


Senfronia Thompson
Sheryl Cole
Kyle Kacal
Ken King
Bill Zedler


Dawn Buckingham

Bill Caption

Relating to health benefit plan coverage of prescription drugs for stage-four advanced, metastatic cancer.

Fiscal Notes

No significant fiscal implication to the State is anticipated relating to prescription drug coverage for stage-four advanced, metastatic cancer. According to the Health and Human Services Commission (HHSC), the fiscal implications of the bill cannot be determined at this time relating to the uncertainty of prescription drug coverage for associated conditions of stage-four advanced, metastatic cancer.

Bill Analysis

HB 1584 would prohibit a health benefit plan from requiring step therapy for patients with stage-four advanced metastatic cancer and associated conditions.

Vote Recommendation Notes

Texas Action opposes HB 1584 because it infringes on limited government principles. While this is an extremely sympathetic situation, we generally oppose governmental interference with private health benefit plan providers that mandates the type of coverage and mitigating processes that the provider is allowed or required to provide. The litany of these types of mandates have contributed to unaffordable health care costs and impeded access to health insurance. While this particular mandate might not raise overall rates perceptibly, it is the accumulation of many such mandates that have contributed to the problem.